ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HIN Heart Cdi 35:1

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Heart Cdi 35:1 ASX:HIN Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

HeartWare Schedules Second Quarter Conference Call And Webcast

19/07/2013 11:00am

PR Newswire (US)


Heartware International (ASX:HIN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Heartware International Charts.

FRAMINGHAM, Mass. and SYDNEY, July 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2013, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, August 8, 2013. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the second quarter and business outlook.  The call may be accessed by dialing 1-877-941-2321 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9666.

A live webcast of the call will also be available in the Investor section at the Company's website (http://ir.heartware.com/). A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 30 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com 
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Copyright 2013 PR Newswire

1 Year Heartware International Chart

1 Year Heartware International Chart

1 Month Heartware International Chart

1 Month Heartware International Chart

Your Recent History

Delayed Upgrade Clock